Maria Walz

Maria Walz

Auto-generated profile, based on publicly available information

Maria Walz

University of Freiburg 1 Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine Freiburg, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Cancer Research Communications
Verified
Journal Article
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer. Significance: We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
NaJa cells differ in their response to drug treatment. A, Colony formation assay of NaJa cells treated with vemurafenib (V), encorafenib (E), and trametinib (T) at the indicated concentrations for 10 days. Shown is a representative result from three biological replicates. B–D, Quantification of the data shown in A. Data are presented as the mean ± SD and were normalized to the DMSO control (n = 3). Statistical significance was calculated using one-way ANOVA and Dunnett multiple comparisons test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. E, Phospho-RTK array of NaJa cells treated with 1 μmol/L vemurafenib (Vem), 0.5 μmol/L encorafenib (Enco), or 50 nmol/L trametinib (Tram) for 5 days. Shown are the log2 FCs of treated cells versus DMSO control. Array membranes and cell line specific heatmaps are displayed in Supplementary Fig. S7. F, Western blot showing the effect of a 5-day treatment of the NaJa cells on various signaling pathways. G, Western blot and quantification of HER2 and HER3 (n = 4). Basal EGFR expression was quantified based on data in (F), and five additional biological replicates normalized to the internal loading control. Data are presented as the mean ± SD and were normalized to NaJa-F for comparison. Statistical significance was calculated using one-way ANOVA and Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. H, Bulk RNA-seq of NaJa cells treated with 0.5 μmol/L encorafenib for 1 day or 5 days showing upregulation (red) or downregulation (blue) of ERK target genes and the adjusted P value (bubble size).

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S7 shows the membranes from the phospho-RTK array of NaJa cells and detailed cell line specific heatmaps.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
List of antibodies used in this study

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer
Supplementary Figure S2 shows the effect of encorafenib, afatinib and trametinib treatment on BPAC organoid viability.

16 February 2026
Verified
Other
Open access
JTJasmin Traichel
Jasmin Traichel
AMAriane Metzger
Ariane Metzger
MWMaria Walz
Maria Walz
RFReinhild Feuerstein
Reinhild Feuerstein
NWNadine Wohlfeil
Nadine Wohlfeil
TBTilman Brummer
Tilman Brummer